Option Investor
Newsletter

CYPB CLOSED OUT

HAVING TROUBLE PRINTING?
Printer friendly version

CYPB CLOSED OUT


CYPB CLOSED OUT AT $2.75 NET DEBIT for a NET LOSS of $2.25

A Key Phase III clinical trial showed its drug milnacipran was
statistically ineffective in treating fibromyalgia, a
condition which can cause chronic muscle pain and stiffness.
Despite the companies plans to pursue additional Phase III
clinical trials for the drug, we are forced to close the position at this time.

The break below $5.00 and close for the day below $5.00
forces us to close out our OCT 7.5 Put (QGY-VU) at $2.75. with a NET LOSS
of $2.25 as we stated on our previous email.


Option Writers Newsletter Archives